Collection 3 (Sep 2022 - Aug 2023) Articles

Articles
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Ray KK, Kallend D, Leiter LA, et al.
Journal:
Eur Heart J

First published: November 4, 2022 DOI: 10.1093/eurheartj/ehac615
View
- Share
Articles
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
Ray KK, Raal FJ, Kallend DG, et al.
Journal:
Eur Heart J

First published: November 4, 2022 DOI: 10.1093/eurheartj/ehac594
View
- Share
Articles
Cardiovascular Risk Assessment and Management for Pediatricians
Schipper HS, de Ferranti S
Journal:
Pediatrics

First published: November 2, 2022 DOI: 10.1542/peds.2022-057957
View
- Share
Articles
Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
Hedegaard BS, Bork CS, Kaltoft M, et al.
Journal:
J Am Coll Cardiol

First published: November 1, 2022 DOI: 10.1016/j.jacc.2022.09.021
View
- Share
Articles
HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity?
Ferdinand KC
Journal:
J Am Coll Cardiol

First published: November 1, 2022 DOI: 10.1016/j.jacc.2022.10.007
View
- Share
Articles
Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic
Chiou TT, Tomasi K, Taub PR, et al.
Journal:
J Clin Lipidol

First published: November 1, 2022 DOI: 10.1016/j.jacl.2022.10.009
View
- Share
Articles
Underutilisation of combination therapy in lipid lowering: A missed opportunity
Sener YZ, Tokgözoğlu L
Journal:
European Journal of Preventive Cardiology

First published: November 1, 2022 DOI: 10.1093/eurjpc/zwac251
View
- Share
Articles
Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab
Schwartz G, Szarek M, Zeiher A, et al.
Journal:
J Am Coll Cardiol

First published: October 31, 2022 DOI: 10.1016/j.jacc.2022.09.035
View
- Share
Articles
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins
McQueen RB, Baum SJ, Louie MJ, et al.
Journal:
Am J Cardiovasc Drugs

First published: October 31, 2022 DOI: 10.1007/s40256-022-00552-7
View
- Share
Articles
Adherence to statin therapy – it seems we know everything, yet we do nothing…
Banach M, Penson PE
Journal:
European Heart Journal Open

First published: October 26, 2022 DOI: 10.1093/ehjopen/oeac071
View
- Share
Articles
Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study
Deshotels MR, Sun C, Nambi V, et al.
Journal:
J Am Heart Assoc

First published: October 26, 2022 DOI: 10.1161/JAHA.122.026762
View
- Share
Articles
Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
Desai NR, Farbaniec M, Karalis DG
Journal:
Clin Cardiol

First published: October 20, 2022 DOI: 10.1002/clc.23935
View
- Share

1 … 4 5 6 7 8

Collection 3 (Sep 2022 - Aug 2023) Articles

Articles

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray KK, Kallend D, Leiter LA, et al.

Articles

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Ray KK, Raal FJ, Kallend DG, et al.

Articles

Cardiovascular Risk Assessment and Management for Pediatricians

Schipper HS, de Ferranti S

Articles

Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease

Hedegaard BS, Bork CS, Kaltoft M, et al.

Articles

HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity?

Ferdinand KC

Articles

Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic

Chiou TT, Tomasi K, Taub PR, et al.

Articles

Underutilisation of combination therapy in lipid lowering: A missed opportunity

Sener YZ, Tokgözoğlu L

Articles

Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

Schwartz G, Szarek M, Zeiher A, et al.

Articles

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins

McQueen RB, Baum SJ, Louie MJ, et al.

Articles

Adherence to statin therapy – it seems we know everything, yet we do nothing…

Banach M, Penson PE

Articles

Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study

Deshotels MR, Sun C, Nambi V, et al.

Articles

Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease

Desai NR, Farbaniec M, Karalis DG

Articles

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray KK, Kallend D, Leiter LA, et al.

Share

Articles

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Ray KK, Raal FJ, Kallend DG, et al.

Share

Articles

Cardiovascular Risk Assessment and Management for Pediatricians

Schipper HS, de Ferranti S

Share

Articles

Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease

Hedegaard BS, Bork CS, Kaltoft M, et al.

Share

Articles

HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity?

Ferdinand KC

Share

Articles

Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic

Chiou TT, Tomasi K, Taub PR, et al.

Share

Articles

Underutilisation of combination therapy in lipid lowering: A missed opportunity

Sener YZ, Tokgözoğlu L

Share

Articles

Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

Schwartz G, Szarek M, Zeiher A, et al.

Share

Articles

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins

McQueen RB, Baum SJ, Louie MJ, et al.

Share

Articles

Adherence to statin therapy – it seems we know everything, yet we do nothing…

Banach M, Penson PE

Share

Articles

Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study

Deshotels MR, Sun C, Nambi V, et al.

Share

Articles

Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease

Desai NR, Farbaniec M, Karalis DG

Share